Profile of blonanserin for the treatment of schizophrenia

References

• InselTRRethinking schizophreniaNature2010468732118719321068826
   PubMed Web of Science ®Google Scholar
• MiyamotoSDuncanGEGoffDCLiebermanJATherapeutics of SchizophreniaDavisKLCharneyDCoyleJTNemeroffCNeuropsychopharmacology: The Fifth Generation of ProgressPhiladelphiaLippincott Williams & Wilkins2002775807
   Google Scholar
• MiyamotoSMiyakeNJarskogLFFleischhackerWWLiebermanJAPharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agentsMol Psychiatry201217121206122722584864
   PubMed Web of Science ®Google Scholar
• MiyamotoSFleischhackerWWLiebermanJAPharmacologic treatment of schizophreniaLiebermanJAMurrayRMComprehensive Care of Schizophrenia (Second Edition): A Textbook of Clinical ManagementNew YorkOxford University Press201277138
   Google Scholar
• JonesPBBarnesTRDaviesLRandomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1)Arch Gen Psychiatry200663101079108717015810
   PubMed Web of Science ®Google Scholar
• KahnRSFleischhackerWWBoterHEffectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trialLancet200837196181085109718374841
   PubMed Web of Science ®Google Scholar
• LeuchtSCorvesCArbterDEngelRRLiCDavisJMSecond-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysisLancet20093739657314119058842
   PubMed Web of Science ®Google Scholar
• LiebermanJAStroupTSMcEvoyJPEffectiveness of antipsychotic drugs in patients with chronic schizophreniaN Engl J Med2005353121209122316172203
   PubMed Web of Science ®Google Scholar
• BuchananRWKreyenbuhlJKellyDLThe 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statementsSchizophr Bull2010361719319955390
   PubMed Web of Science ®Google Scholar
• HasanAFalkaiPWobrockTWorld Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistanceWorld J Biol Psychiatry201213531837822834451
   PubMed Web of Science ®Google Scholar
• LehmanAFLiebermanJADixonLBPractice Guideline for the Treatment of Patients with Schizophrenia2nd edAm J Psychiatry2004161Suppl 215615000267
   PubMed Web of Science ®Google Scholar
• MiyakeNMiyamotoSJarskogLFNew serotonin/dopamine antagonists for the treatment of schizophrenia: are we making real progress?Clin Schizophr Relat Psychoses20126312213323006237
   PubMedGoogle Scholar
• KishiTMatsudaYNakamuraHIwataNBlonanserin for schizophrenia: Systematic review and meta-analysis of double-blind, randomized, controlled trialsJ Psychiatr Res201347214915423131856
   PubMed Web of Science ®Google Scholar
• UneTKurumiyaSPharmacological profile of blonanserinJpn J Clin Psychopharmacol200710712631272
   Google Scholar
• MurasakiMPreclinical and clinical features of blonanserinJpn J Clin Psychopharmacol2008115855868
   Google Scholar
• DeeksEDKeatingGMBlonanserin: a review of its use in the management of schizophreniaCNS Drugs2010241658420030420
   PubMed Web of Science ®Google Scholar
• OkaMNodaYOchiYPharmacological profile of AD-5423, a novel antipsychotic with both potent dopamine-D2 and serotonin-S2 antagonist propertiesJ Pharmacol Exp Ther199326411581658093723
   PubMed Web of Science ®Google Scholar
• MurasakiMNishikawaHIshibashiTDopamine-serotonin antagonist: Receptor binding profile of a novel antipsychotic blonanserinJpn J Clin Psychopharmacol2008115845854
   Google Scholar
• OhoyamaKYamamuraSHamaguchiTEffect of novel atypical antipsychotic, blonanserin, on extracellular neurotransmitter level in rat prefrontal cortexEur J Pharmacol20116531–3475721147094
   PubMed Web of Science ®Google Scholar
• Lonasen® (blonanserin) [interview form]Osaka, JapanDainippon Sumitomo Pharma Co, Ltd2012
   Google Scholar
• SuzukiHGenKThe relationship between the daily dose, the plasma concentration of blonanserin, and its plasma anti-dopamine D2 and anti-serotonin 5-HT2A activityHum Psychopharmacol201025434234620521325
   PubMed Web of Science ®Google Scholar
• InoueTOsadaKTagawaMBlonanserin, a novel atypical antipsychotic agent not actively transported as substrate by P-glycoproteinProg Neuropsychopharmacol Biol Psychiatry201239115616222691713
   PubMed Web of Science ®Google Scholar
• ArakawaROkumuraMItoHPositron emission tomography measurement of dopamine D(2) receptor occupancy in the pituitary and cerebral cortex: relation to antipsychotic-induced hyperprolactinemiaJ Clin Psychiatry20107191131113720361897
   PubMed Web of Science ®Google Scholar
• TatenoAPET evaluation for dopamine D2 receptor occupancy of blonanserin in schizophrenia patientsJpn J Clin Psychopharmacol2011142334341
   Google Scholar
• SaruwatariJYasui-FurukoriNInoueYKanekoSEffect of dose timing in relation to food intake on systemic exposure to blonanserinEur J Clin Pharmacol201066989990220490472
   PubMed Web of Science ®Google Scholar
• GarciaERobertMPerisFNakamuraHSatoNTerazawaYThe efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: a randomized, double-blind, placebo-controlled, multicentre studyCNS Drugs200923761562519552488
   PubMed Web of Science ®Google Scholar
• MurasakiMClinical evaluation of blonanserin for schizophrenia: a randomized controlled study comparing blonanserin with haloperidolJpn J Clin Psychopharmacol2007101120592079
   Google Scholar
• MiuraSClinical evaluation of blonanserin for schizophrenia: a randomized controlled study comparing blonanserin with risperidoneJpn J Clin Psychopharmacol2008112297314
   Google Scholar
• YangJBahkWMChoHSEfficacy and tolerability of Blonanserin in the patients with schizophrenia: a randomized, double-blind, risperidone-compared trialClin Neuropharmacol201033416917520661022
   PubMed Web of Science ®Google Scholar
• MurasakiMLong-term clinical study of blonanserin for schizophrenia: a multicenter open study to determine safety and effectiveness in schizophrenic patients (Kanagawa Region Clinical Psychopharmacology Study Group)Jpn J Clin Psychopharmacol2007101222412257
   Google Scholar
• KinoshitaTLong-term clinical study of blonanserin for schizophrenia: a multicenter open study to determine safety and effectiveness in schizophrenic patients (Japan-wide study)Jpn J Clin Psychopharmacol2008111135153
   Google Scholar
• OsadaKMiyamotoSMarutaSMiyakeNNakanoMYamaguchiNLong-term clinical study of blonanserin for schizophrenia: a multicenter open study to assess the safety and efficacy in patients with schizophrenia (Continuation of two long-term studies by request from patients)Jpn J Clin Psychopharmacol2009121123372351
   Google Scholar
• GreenMFKernRSBraffDLMintzJNeurocognitive deficits and functional outcome in schizophrenia: are we measuring the “right stuff”?Schizophr Bull200026111913610755673
   PubMed Web of Science ®Google Scholar
• GoldJMHarveyPDCognitive deficits in schizophreniaPsychiatr Clin North Am19931622953128332566
   PubMed Web of Science ®Google Scholar
• Mesholam-GatelyRIGiulianoAJGoffKPFaraoneSVSeidmanLJNeurocognition in first-episode schizophrenia: a meta-analytic reviewNeuropsychology200923331533619413446
   PubMed Web of Science ®Google Scholar
• BozikasVPAndreouCLongitudinal studies of cognition in first episode psychosis: a systematic review of the literatureAust N Z J Psychiatry20114529310821320033
   PubMed Web of Science ®Google Scholar
• BilderRMGoldmanRSRobinsonDNeuropsychology of first-episode schizophrenia: initial characterization and clinical correlatesAm J Psychiatry2000157454955910739413
   PubMed Web of Science ®Google Scholar
• SaykinAJShtaselDLGurRENeuropsychological deficits in neuroleptic naive patients with first-episode schizophreniaArch Gen Psychiatry19945121241317905258
   PubMed Web of Science ®Google Scholar
• WolwerWBrinkmeyerJRiesbeckMNeuropsychological impairments predict the clinical course in schizophreniaEur Arch Psychiatry Clin Neurosci2008258 Suppl 5283418985291
   PubMed Web of Science ®Google Scholar
• MatsuiMSumiyoshiTAraiHHiguchiYKurachiMCognitive functioning related to quality of life in schizophreniaProg Neuropsychopharmacol Biol Psychiatry200832128028717884266
   PubMed Web of Science ®Google Scholar
• MiyakeNMiyamotoSTakeuchiAEffect of new-generation antipsychotic blonanserin on cognitive impairment in schizophrenia: A randomized double-blind comparison with risperidoneJpn J Clin Psychopharmacol2008112315326
   Google Scholar
• TenjinTMiyamotoSMiyakeNEffect of blonanserin on cognitive function in antipsychotic-naive first-episode schizophreniaHum Psychopharmacol20122719010022278973
   PubMed Web of Science ®Google Scholar
• KanedaYSumiyoshiTKeefeRIshimotoYNumataSOhmoriTBrief assessment of cognition in schizophrenia: validation of the Japanese versionPsychiatry Clin Neurosci200761660260918081619
   PubMed Web of Science ®Google Scholar
• KanedaYImakuraAFujiiAOhmoriTSchizophrenia Quality of Life Scale: validation of the Japanese versionPsychiatry Res20021131–210711312467950
   PubMed Web of Science ®Google Scholar
• MiyamotoSMerrillDBLiebermanJAFleischhackerWWMarderSRAntipsychotic DrugsTasmanAKayJLiebermanJAFirstMBMajMPsychiatry3rd edChichesterJohn Wiley & Sons200821612201
   Google Scholar